VBI-003 / Virtuoso Therap - LARVOL DELTA

Preclinical safety evaluation of VP1186, a CD47xEpCAM bispecific antibody (AACR 2025) - "Pharmacokinetic (PK) analysis confirmed good drug exposure. These findings, combined with the potent anti-tumor activity of VP1186, support its further clinical evaluation as a potential treatment for CD47- and EpCAM-expressing cancers, particularly small cell lung cancer, gastric cancer, ovarian cancer and colorectal cancer."

IO biomarker • Preclinical • Colorectal Cancer • Gastric Cancer • Lung Cancer • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • CD47 • SIRPA

VBI‑003, a CD47xEpCAM bispecific antibody as a potential treatment for colorectal and small cell lung cancers (AACR 2023) - "CD47/SIRPα axis is an important checkpoint of innate immune system and is often exploited by tumor cells to evade host immune surveillance. In conclusion, VBI‑003 has potent single agent activity in SCLC tumor models and combined synergistically with irinotecan in CRC models. Our data support further investigation of VBI‑003 as a treatment for CD47 and EpCAM expressing SCLC and CRC."

Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor • CD47 • SIRPA

Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PRNewswire) - "Virtuoso Therapeutics...announced that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs at the American Associate for Cancer Research (AACR) 2023 Annual Meeting."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Skin Cancer • Small Cell Lung Cancer • Solid Tumor • Thoracic Cancer